These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 17033233)

  • 1. [Prolonged survival of gefitinib treatment in patients with advanced and previously treated non-small cell lung cancer].
    Nishikawa M; Kusano N; Yoshimoto N; Ito M; Kakemizu N; Nozaki M; Fujiwara M; Momiyama M; Kido Y
    Gan To Kagaku Ryoho; 2006 Oct; 33(10):1437-40. PubMed ID: 17033233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical significance of epidermal growth factor receptor gene mutations on treatment outcome after first-line cytotoxic chemotherapy in Japanese patients with non-small cell lung cancer.
    Hotta K; Kiura K; Toyooka S; Takigawa N; Soh J; Fujiwara Y; Tabata M; Date H; Tanimoto M
    J Thorac Oncol; 2007 Jul; 2(7):632-7. PubMed ID: 17607119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective study of second-line chemotherapy for non-small cell lung cancer selected according to EGFR gene status.
    Oshita F; Miyagi Y; Honda T; Murakami S; Kondo T; Saito H; Noda K; Yokose T; Kameda Y; Sakuma Y; Obata M; Yamada K
    J Exp Ther Oncol; 2010; 8(4):313-9. PubMed ID: 21222363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II trial of gefitinib monotherapy in chemotherapy-naïve patients of 75 years or older with advanced non-small cell lung cancer.
    Ebi N; Semba H; Tokunaga SJ; Takayama K; Wataya H; Kuraki T; Yamamoto H; Akamine SJ; Okamoto I; Nakanishi Y;
    J Thorac Oncol; 2008 Oct; 3(10):1166-71. PubMed ID: 18827614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
    Dudek AZ; Kmak KL; Koopmeiners J; Keshtgarpour M
    Lung Cancer; 2006 Jan; 51(1):89-96. PubMed ID: 16290256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study.
    Maemondo M; Minegishi Y; Inoue A; Kobayashi K; Harada M; Okinaga S; Morikawa N; Oizumi S; Tanaka T; Isobe H; Kudoh S; Hagiwara K; Nukiwa T; Gemma A
    J Thorac Oncol; 2012 Sep; 7(9):1417-22. PubMed ID: 22895139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of erlotinib for acquired resistance to gefitinib in patients with advanced non-small cell lung cancer.
    Horiike A; Yamamoto N; Tanaka H; Yanagitani N; Kudo K; Ohyanagi F; Ono A; Naito T; Murakami H; Horai T; Nishio M
    Anticancer Res; 2014 Apr; 34(4):1975-81. PubMed ID: 24692734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of survival in advanced non-small cell lung cancer patients in the pre- and post-gefitinib eras.
    Kim HS; Park K; Jun HJ; Yi SY; Lee J; Ahn JS; Park YH; Kim S; Lee S; Ahn MJ
    Oncology; 2009; 76(4):239-46. PubMed ID: 19246948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive factors of gefitinib antitumor activity in East Asian advanced non-small cell lung cancer patients.
    Chang GC; Tsai CM; Chen KC; Yu CJ; Shih JY; Yang TY; Lin CP; Hsu JY; Chiu CH; Perng RP; Yang PC; Yang CH
    J Thorac Oncol; 2006 Jul; 1(6):520-5. PubMed ID: 17409911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.
    Kim ES; Hirsh V; Mok T; Socinski MA; Gervais R; Wu YL; Li LY; Watkins CL; Sellers MV; Lowe ES; Sun Y; Liao ML; Osterlind K; Reck M; Armour AA; Shepherd FA; Lippman SM; Douillard JY
    Lancet; 2008 Nov; 372(9652):1809-18. PubMed ID: 19027483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three-year survival in metastatic non-small cell lung cancer treated with gefitinib.
    Costa DB; Schumer ST
    Lung Cancer; 2006 Jul; 53(1):123-4. PubMed ID: 16723171
    [No Abstract]   [Full Text] [Related]  

  • 12. Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations.
    Morita S; Okamoto I; Kobayashi K; Yamazaki K; Asahina H; Inoue A; Hagiwara K; Sunaga N; Yanagitani N; Hida T; Yoshida K; Hirashima T; Yasumoto K; Sugio K; Mitsudomi T; Fukuoka M; Nukiwa T
    Clin Cancer Res; 2009 Jul; 15(13):4493-8. PubMed ID: 19531624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gefitinib monotherapy in advanced nonsmall cell lung cancer: a large Western community implementation study.
    van Puijenbroek R; Bosquée L; Meert AP; Schallier D; Goeminne JC; Tits G; Collard P; Nackaerts K; Canon JL; Duplaquet F; Galdermans D; Germonpré P; Azerad MA; Vandenhoven G; De Greve J; Vansteenkiste J
    Eur Respir J; 2007 Jan; 29(1):128-33. PubMed ID: 17005582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01): an open-label, phase 3 trial.
    Sun JM; Lee KH; Kim SW; Lee DH; Min YJ; Yun HJ; Kim HK; Song HS; Kim YH; Kim BS; Hwang IG; Lee K; Jo SJ; Lee JW; Ahn JS; Park K; Ahn MJ;
    Cancer; 2012 Dec; 118(24):6234-42. PubMed ID: 22674612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Exon-dependent Subgroup-analysis of the Non-interventional REASON-Study: PFS and OS in EGFR-mutated NSCLC Patients Treated with Gefitinib or Chemotherapy].
    Schuette W; Dietel M; Thomas M; Eberhardt W; Griesinger F; Zirrgiebel U; Radke S; Schirmacher P
    Pneumologie; 2016 Aug; 70(8):514-21. PubMed ID: 27512931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-dose gefitinib treatment for patients with advanced non-small cell lung cancer harboring sensitive epidermal growth factor receptor mutations.
    Satoh H; Inoue A; Kobayashi K; Maemondo M; Oizumi S; Isobe H; Gemma A; Saijo Y; Yoshizawa H; Hagiwara K; Nukiwa T
    J Thorac Oncol; 2011 Aug; 6(8):1413-7. PubMed ID: 21681118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gefitinib compared with systemic chemotherapy as first-line treatment for chemotherapy-naive patients with advanced non-small cell lung cancer: a meta-analysis of randomised controlled trials.
    Wang F; Wang LD; Li B; Sheng ZX
    Clin Oncol (R Coll Radiol); 2012 Aug; 24(6):396-401. PubMed ID: 22019482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.
    Soria JC; Wu YL; Nakagawa K; Kim SW; Yang JJ; Ahn MJ; Wang J; Yang JC; Lu Y; Atagi S; Ponce S; Lee DH; Liu Y; Yoh K; Zhou JY; Shi X; Webster A; Jiang H; Mok TS
    Lancet Oncol; 2015 Aug; 16(8):990-8. PubMed ID: 26159065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial.
    Shi Y; Zhang L; Liu X; Zhou C; Zhang L; Zhang S; Wang D; Li Q; Qin S; Hu C; Zhang Y; Chen J; Cheng Y; Feng J; Zhang H; Song Y; Wu YL; Xu N; Zhou J; Luo R; Bai C; Jin Y; Liu W; Wei Z; Tan F; Wang Y; Ding L; Dai H; Jiao S; Wang J; Liang L; Zhang W; Sun Y
    Lancet Oncol; 2013 Sep; 14(10):953-61. PubMed ID: 23948351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gefitinib as first-line treatment in elderly epidermal growth factor receptor-mutated patients with advanced lung adenocarcinoma: results of a Nagano Lung Cancer Research Group study.
    Asami K; Koizumi T; Hirai K; Ameshima S; Tsukadaira A; Morozumi N; Morikawa A; Atagi S; Kawahara M
    Clin Lung Cancer; 2011 Nov; 12(6):387-92. PubMed ID: 21729650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.